Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen

Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, HER2 overexpressing breast cancer cells respond poorly to tamoxifen therapy presumably by pass. The molecular mechanisms underlying development of tamoxifen resistance have not been well established. Rec...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cancer Res
Hlavní autoři: Yin, Li, Pan, Xiaohua, Zhang, Xin-Tian, Guo, Yu-Ming, Wang, Zhao-Yi, Gong, Yaoqin, Wang, Molin
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396031/
https://ncbi.nlm.nih.gov/pubmed/25973295
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky